ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Immuneering Corporation

Immuneering Corporation (IMRX)

1.415
-0.065
( -4.39% )
Updated: 13:37:53

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
1.415
Bid
1.41
Ask
1.42
Volume
41,965
1.40 Day's Range 1.50
0.00 52 Week Range 0.00
Market Cap
Previous Close
1.48
Open
1.49
Last Trade
12
@
1.4199
Last Trade Time
13:54:00
Financial Volume
$ 60,611
VWAP
1.4443
Average Volume (3m)
-
Shares Outstanding
29,283,272
Dividend Yield
-
PE Ratio
-0.77
Earnings Per Share (EPS)
-1.83
Revenue
-
Net Profit
-53.47M

About Immuneering Corporation

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary comput... Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to leading pharmaceutical and biotechnology companies. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Immuneering Corporation is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker IMRX. The last closing price for Immuneering was $1.48. Over the last year, Immuneering shares have traded in a share price range of $ 0.00 to $ 0.00.

Immuneering currently has 29,283,272 shares outstanding. The market capitalization of Immuneering is $41.29 million. Immuneering has a price to earnings ratio (PE ratio) of -0.77.

IMRX Latest News

Immuneering to Present at the Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
GRDIGRIID Infrastructure Inc
$ 1.4136
(152.43%)
126.75M
ZAPPZapp Electric Vehicles Group Ltd
$ 3.3784
(148.41%)
79.75M
MGOLMGO Global Inc
$ 0.765
(66.88%)
150.52M
RELIReliance Global Group Inc
$ 0.5526
(41.29%)
115.5M
FEMYFemasys Inc
$ 1.28
(34.03%)
1.3M
WHLRWheeler Real Estate Investment Trust Inc
$ 2.71
(-82.76%)
126.41k
KAVLKaival Brands Innovations Group Inc
$ 2.84
(-36.89%)
943.7k
TRVNTrevena Inc
$ 0.2395
(-32.42%)
36.93M
MBIOMustang Bio Inc
$ 0.58
(-31.77%)
34.59M
NLSPNLS Pharmaceutics Ltd
$ 0.1875
(-30.58%)
12.76M
NVDANVIDIA Corporation
$ 131.25
(-3.19%)
354.53M
NKLANikola Corporation
$ 0.3521
(-26.78%)
189.33M
SMXSMX Security Matters Public Company
$ 0.159
(33.61%)
163.89M
MGOLMGO Global Inc
$ 0.765
(66.88%)
150.52M
GRDIGRIID Infrastructure Inc
$ 1.4136
(152.43%)
126.75M

IMRX Discussion

View Posts
Monksdream Monksdream 2 months ago
IMRX under $2
๐Ÿ‘๏ธ0
axelvento axelvento 2 months ago
Peter Feinberg, recently bought US$183k worth of stock, paying US$2.44 for each share
๐Ÿ‘๏ธ0
herbied47 herbied47 2 months ago
A lot to like except the share price sadly.
๐Ÿ‘๏ธ0
axelvento axelvento 2 months ago
Results:IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

IMM-1-104 showed promising combination effects when treated with gemcitabine (GEM), paclitaxel (PAC) or fluorouracil (5FU) in 3D-tumor growth assay (TGA) pancreatic cancer models.
IMM-1-104 was synergistic with chemotherapy in animal models of pancreatic cancer.
In a human pancreatic cancer cell line (MIA PaCa-2) tumor xenograft model, IMM-1-104 alone showed greater tumor growth inhibition (TGI) and better durability than any single or combination chemotherapy tested.
At day 39, antitumor activity (TGI%) was 103% for IMM-1-104 at 125 mg/kg BID PO, 25.2% for GEM at 60 mg/kg IP Q4D, 62.2% for PAC at 10 mg/kg IV Q4D, and 36.6% for 5FU at 50 mg/kg IP Q4D.
In the Phase 2a portion of Immuneeringโ€™s ongoing IMM-1-104 Phase 1/2a clinical trial, IMM-1-104 is being evaluated as both monotherapy and in select combinations with approved chemotherapeutic agents. The Phase 2a portion includes five arms, three of which focus on patients with pancreatic cancer. Patients are now on treatment in multiple arms of the ongoing Phase 2a trial, including multiple patients with pancreatic cancer who are being treated with IMM-1-104 in combination with chemotherapy in the first-line setting. The company expects initial data from multiple Phase 2a arms in 2024.
https://ir.immuneering.com/news-releases/news-release-details/imm-1-104-synergistic-chemotherapy-pancreatic-cancer-models
๐Ÿ‘๏ธ0
axelvento axelvento 3 months ago
The top 5 shareholders own 54% of the company

the third-largest shareholder, also happens to hold the title of Member of the Board of Directors
๐Ÿ‘๏ธ0
axelvento axelvento 3 months ago
Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

Company expects multiple readouts from its Phase 1/2a clinical trial in 2024
๐Ÿ‘๏ธ0
axelvento axelvento 3 months ago
Peter Feinberg, recently bought US$183k worth of stock, paying US$2.44 for each share.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imrx/immuneering/news/insider-spends-us183k-buying-more-shares-in-immuneering
๐Ÿ‘๏ธ0
herbied47 herbied47 3 months ago
Itโ€™s easy to find in the filings. Not that is has helped the share price any.
๐Ÿ‘๏ธ0
dealerschool2006 dealerschool2006 3 months ago
how do you know insider buying has occurred for IMRX???
๐Ÿ‘๏ธ0
herbied47 herbied47 3 months ago
Good to see that insider buying! Give it a week or two and I wouldnโ€˜t be surprised to see it trading back between $5 to $6. Certainly no need to be a seller now. Have a great day all and God bless!
๐Ÿ‘๏ธ0
glenn1919 glenn1919 3 months ago
IMRX................................https://stockcharts.com/h-sc/ui?s=IMRX&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
herbied47 herbied47 3 months ago
Should be back over $5 soon.
๐Ÿ‘๏ธ0
axelvento axelvento 3 months ago
management started dosing patients in the phase IIa portion of the study. This portion will evaluate a 320mg dose of IMM-1-104 as monotherapy in pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC) and melanoma, and as combination therapy in PDAC.

Initial data from the phase IIa portion is expected later this year
๐Ÿ‘๏ธ0
Monksdream Monksdream 3 months ago
IMRX under $2
๐Ÿ‘๏ธ0
Monksdream Monksdream 3 months ago
IMRX new 52. Lo
๐Ÿ‘๏ธ0
willlbone willlbone 3 months ago
Maybe insiders got some news, like dilution is coming to pay for Phase 2.
๐Ÿ‘๏ธ0
dealerschool2006 dealerschool2006 3 months ago
IMRX fell today after positive results...
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock